Bolt Biotherapeutics Approves Key Governance Changes

Bolt Biotherapeutics ( (BOLT) ) has issued an update.

On May 27, 2025, Bolt Biotherapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and financial strategies. During the meeting, two directors were elected to the board, the selection of PricewaterhouseCoopers LLP as the independent auditor for 2025 was ratified, and an amendment for a reverse stock split was approved. These decisions are expected to influence the company’s operational strategies and financial structuring, potentially impacting shareholder value and market perception.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Spark’s Take on BOLT Stock

According to Spark, TipRanks’ AI Analyst, BOLT is a Neutral.

Bolt Biotherapeutics faces significant challenges in financial performance and valuation, with ongoing losses impacting its attractiveness to investors. The technical analysis shows bearish signals, suggesting weak market sentiment. Structural improvements are necessary for enhancing financial health and stock performance.

To see Spark’s full report on BOLT stock, click here.

More about Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative immuno-oncology therapeutics. The company aims to harness the power of the immune system to combat cancer, emphasizing targeted therapies that can potentially improve patient outcomes.

Average Trading Volume: 318,348

Technical Sentiment Signal: Sell

Current Market Cap: $12.27M

For an in-depth examination of BOLT stock, go to TipRanks’ Stock Analysis page.